Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.54 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GLI1 | P08151 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197361 | 1.00 | PRCP (0.54) | PRCPTERTHTR2CHTR2BNOS2 | |
| SCHEMBL8789836 | 1.00 | PRCP (0.54) | PRCPTERTHTR2CHTR2BNOS2 | |
| Hydrochloric Acid SCHEMBL7702578 | 0.98 | PRCP (0.53) | PRCPTERTHTR2CHTR2BNOS2 | |
| Hydrochloric Acid SCHEMBL11516357 | 0.98 | PRCP (0.53) | PRCPTERTHTR2CHTR2BNOS2 | |
| Glycine SCHEMBL7541811 | 0.92 | PRCP (0.48) | PRCPTERTHTR2CHTR2BNOS2 | |
| SCHEMBL5959019 | 0.84 | PRCP (0.44) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL620066 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL620067 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL8789170 | 0.84 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL943040 | 0.83 | PRCP (0.58) | PRCPTERTHTR2CHTR2BNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIV STRASBOURG (FR) | 2023-06-08 | — | — | US | disclosed |
| US-7309689-B2 | Sustained peptide-release formulation | PEPTECH LIMITED (AU) | 2007-12-18 | — | — | US | disclosed |
| WO-2004087190-A1 | METHOD FOR THE TREATMENT OF PROSTATE CANCER | GENIX THERAPEUTICS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-6337318-B1 | DRUGS FOR PEPTIDE AGONIST | PEPTECH, LTD. (AU) | 2002-01-08 | — | — | US | disclosed |
| EP-0021234-B1 | NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF LUTEINIZING HORMONE RELEASING HORMONE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-RE29732-E | Tripeptide | ABBOTT LABORATORIES (US) | 1978-08-15 | — | — | US | disclosed |
| US-4086219-A | LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS | PARKE, DAVIS & COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-3953416-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same | FOLKERS KARL | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GIPR | PRCP 628/4885TERT 4493/4885HTR2C 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.